Effectiveness and Safety of Radium-223 Dichloride

ISBN-13: 9786206581642 / Angielski / Miękka / 60 str.

Mª Alejandra Asensio Ruiz; Manuel Soria Soto

Opis

Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.

O autorze

Graduate in Pharmacy and specialist in Radiopharmacy.